Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; se… Read more
Market Cap & Net Worth: Trinity Biotech plc (TRIB)
Trinity Biotech plc (NASDAQ:TRIB) has a market capitalization of $13.79 Million ($13.79 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26527 globally and #8969 in its home market, demonstrating a 5.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Trinity Biotech plc's stock price $0.74 by its total outstanding shares 18632019 (18.63 Million).
Trinity Biotech plc Market Cap History: 2015 to 2026
Trinity Biotech plc's market capitalization history from 2015 to 2026. Data shows change from $1.10 Billion to $13.79 Million (-34.40% CAGR).
Index Memberships
Trinity Biotech plc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #703 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2261 of 3165 |
Weight: Trinity Biotech plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Trinity Biotech plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Trinity Biotech plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.27x
Trinity Biotech plc's market cap is 0.27 times its annual revenue
0.67x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.10 Billion | $100.19 Million | $21.80 Million | 10.93x | 50.26x |
| 2016 | $644.67 Million | $99.61 Million | -$100.63 Million | 6.47x | N/A |
| 2017 | $475.12 Million | $99.14 Million | -$40.27 Million | 4.79x | N/A |
| 2018 | $213.34 Million | $97.03 Million | $2.39 Million | 2.20x | 89.26x |
| 2019 | $96.27 Million | $90.44 Million | -$4.07 Million | 1.06x | N/A |
| 2020 | $354.94 Million | $101.98 Million | -$6.39 Million | 3.48x | N/A |
| 2021 | $133.22 Million | $81.15 Million | $875.00K | 1.64x | 152.25x |
| 2022 | $92.23 Million | $62.52 Million | -$41.00 Million | 1.48x | N/A |
| 2023 | $39.97 Million | $56.83 Million | -$24.02 Million | 0.70x | N/A |
| 2024 | $16.40 Million | $61.55 Million | -$31.79 Million | 0.27x | N/A |
Competitor Companies of TRIB by Market Capitalization
Companies near Trinity Biotech plc in the global market cap rankings as of March 19, 2026.
Key companies related to Trinity Biotech plc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Trinity Biotech plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Trinity Biotech plc's market cap moved from $1.10 Billion to $ 13.79 Million, with a yearly change of -34.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.79 Million | -6.45% |
| 2025 | $14.74 Million | -10.13% |
| 2024 | $16.40 Million | -58.97% |
| 2023 | $39.97 Million | -56.67% |
| 2022 | $92.23 Million | -30.77% |
| 2021 | $133.22 Million | -62.47% |
| 2020 | $354.94 Million | +268.69% |
| 2019 | $96.27 Million | -54.87% |
| 2018 | $213.34 Million | -55.10% |
| 2017 | $475.12 Million | -26.30% |
| 2016 | $644.67 Million | -41.16% |
| 2015 | $1.10 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Trinity Biotech plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.79 Million USD |
| MoneyControl | $13.79 Million USD |
| MarketWatch | $13.79 Million USD |
| marketcap.company | $13.79 Million USD |
| Reuters | $13.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.